
William B Feldman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12037984/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Payer-Specific Negotiated Prices for Prescription Drugs at Top-Performing US Hospitals. JAMA Internal Medicine, 2022, 182, 83.	5.1	7
2	Switching to Over-the-Counter Availability of Rescue Inhalers for Asthma. JAMA - Journal of the American Medical Association, 2022, 327, 1021.	7.4	10
3	Coverage of New Drugs in Medicare Part D. Milbank Quarterly, 2022, 100, 562-588.	4.4	3
4	Over-the-Counter Availability of Rescue Inhalers for Asthma—Reply. JAMA - Journal of the American Medical Association, 2022, 328, 216.	7.4	1
5	The Future of Drug-Pricing Transparency. New England Journal of Medicine, 2021, 384, 489-491.	27.0	11
6	Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation. Milbank Quarterly, 2021, 99, 240-272.	4.4	14
7	Trends in Medicare Part D Inhaler Spending: 2012–2018. Annals of the American Thoracic Society, 2021, 18, 548-550.	3.2	8
8	Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs. JAMA Network Open, 2021, 4, e218816.	5.9	15
9	Estimating Rebates and Other Discounts Received by Medicare Part D. JAMA Health Forum, 2021, 2, e210626.	2.2	18
10	Empirical Assessment of U.S. Coronavirus Disease 2019 Crisis Standards of Care Guidelines. , 2021, 3, e0496.		2
11	Performance of crisis standards of care guidelines in a cohort of critically ill COVID-19 patients in the United States. Cell Reports Medicine, 2021, 2, 100376.	6.5	8
12	Influenza Vaccine Uptake in the Year After Concurrent vs Separate Influenza and Zoster Immunization. JAMA Network Open, 2021, 4, e2135362.	5.9	1
13	Medicare Spending on Drugs With Accelerated Approval, 2015-2019. JAMA Health Forum, 2021, 2, e213937.	2.2	8
14	Potential Medicare Savings on Inhaler Prescriptions Through the Use of Negotiated Prices and a Defined Formulary. JAMA Internal Medicine, 2020, 180, 454.	5.1	4
15	Projected spending for brand-name drugs in English primary care given US prices: a cross-sectional study. Journal of the Royal Society of Medicine, 2020, 113, 350-359.	2.0	2
16	Drug Prices, Rebates, and Discounts. JAMA - Journal of the American Medical Association, 2020, 324, 399.	7.4	4
17	Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined Formulary. JAMA Internal Medicine, 2020, 180, 597.	5.1	10
18	Public Approval of Exception From Informed Consent in Emergency Clinical Trials. JAMA Network Open, 2019, 2, e197591.	5.9	21

William B Feldman

#	Article	IF	CITATIONS
19	When is the right time to discuss ECMO?. Lancet Respiratory Medicine,the, 2019, 7, 939-940.	10.7	Ο
20	Surrogate Endpoints and Drug Regulation: What Is Needed to Clarify the Evidence. Journal of Law, Medicine and Ethics, 2019, 47, 381-387.	0.9	1
21	A Systematic Review Of The Food And Drug Administration's â€~Exception From Informed Consent' Pathway. Health Affairs, 2018, 37, 1605-1614.	5.2	24
22	Trends in Recruitment Rates for Acute Stroke Trials, 1990–2014. Stroke, 2017, 48, 799-801.	2.0	24
23	Response by Feldman et al to Letter Regarding Article, "Trends in Recruitment Rates for Acute Stroke Trials, 1990–2014â€: Stroke, 2017, 48, e145.	2.0	1
24	Effect of waivers of consent on recruitment in acute stroke trials. Neurology, 2016, 86, 1543-1551.	1.1	19
25	Tumor control after surgery for spinal myxopapillary ependymomas: distinct outcomes in adults versus children. Journal of Neurosurgery: Spine, 2013, 19, 471-476.	1.7	80